Molecular imaging using PET plays an important role for the diagnosis of different diseases.
Immuno-PET combines the utilization of PET radionuclides and antibodies/proteins/peptides …

Immuno-PET using desferrioxamine (DFO)-conjugated zirconium-89 ([89Zr] Zr4+)-labeled
antibodies is a powerful tool used for preclinical and clinical molecular imaging. However, a …

Bone sarcomas are devastating primary bone cancers that mostly affect children, young
adults, and the elderly. These aggressive tumors are associated with poor survival, and …

Desferrioxamine (DFO) has long been considered the gold standard chelator for
incorporating [89Zr] Zr4+ in radiopharmaceuticals for positron emission tomography (PET) …

While radiolabelled antibodies have found great utility as PET and SPECT imaging agents
in oncological investigations, a notable shortcoming of these agents is their propensity to …

Purpose: Late-stage, unresectable pancreatic ductal adenocarcinoma (PDAC) is largely
resistant to chemotherapy and consequently has a very poor 5-year survival rate of< 5 …

Site-selective labelling of antibodies (Abs) can circumvent problems from heterogeneity of
conventional conjugation. Here, we evaluate the industrially-applied chemoenzymatic 'Q …

89Zr immuno-PET continues to be assessed in numerous clinical trials. This report
evaluates the use of 89Zr-chloride in the radiolabeling of monoclonal antibodies conjugated …

Hyperbranched polymers have many promising features for drug delivery, owing to their
ease of synthesis, multiple functional group content, and potential for high drug loading with …

Current clinical diagnostic imaging methods for lung metastases are sensitive only to large
tumours (1–2 mm cross-sectional diameter), and early detection can dramatically improve …